Clinical trial
LANN-study: Lantus, Amaryl, Novorapid, Novomix Study
NCT00151697 · Rijnstate Hospital, Other · Completed
Key facts
| NCT number | NCT00151697 |
|---|---|
| Title | LANN-study: Lantus, Amaryl, Novorapid, Novomix Study |
| Official title | New Approach to Treat Type II Diabetes Failing on Maximal Oral Treatment |
| Lead sponsor | Rijnstate Hospital, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus Type II |
| Intervention type | Drug |
| Interventions | Novomix 30, Novorapid and Amaryl, Lantus |
| Enrollment | 150 |
| Start date | May 1, 2005 |
| First posted | Sep 9, 2005 |
| Last update posted | Aug 9, 2011 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: